文献速递脑血管病

新型临床评分联合D-二聚体预测脑静脉血栓形成

Prediction of cerebral venous thrombosis with a new clinical score and D-dimer levels.
PubMed 文献 · Neurology · 2020-06-23

这项前瞻性多中心研究纳入359例临床疑似脑静脉血栓形成(CVT)患者,经神经影像确诊CVT者占26.2%(94/359)。基于6项临床变量建立的评分(AUC 0.889)联合D-二聚体>500 μg/L可优化CVT预测(AUC 0.937),且所有低临床概率且D-二聚体<500 μg/L的患者均无CVT。

要点

  • 6项临床变量评分可分层CVT风险:低概率(0-2分)阴性预测值94.1%。
  • 低概率患者中CVT发生率为5.9%(11/186),且全部D-二聚体>500 μg/L。
  • 临床评分联合D-二聚体>500 μg/L的AUC达0.937,敏感度83%、特异度86.8%。

核心结论

  • 新型临床评分联合D-二聚体可作为CVT的预检评分,低临床概率且D-二聚体<500 μg/L的患者均无CVT。

研究设计与样本

  • 前瞻性多中心研究,纳入359例临床疑似CVT的连续患者,入院时行临床检查、ELISA法测D-二聚体及MR/CT静脉造影。

主要发现

  • 神经影像确诊CVT者占26.2%(94/359)。
  • 6变量评分(癫痫发作4分、已知血栓倾向4分、口服避孕药2分、症状持续>6天2分、最严重头痛1分、局灶神经功能缺损1分)的AUC为0.889。
  • 低概率(0-2分)患者186例(51.8%),其中CVT 11例(5.9%);中概率(3-5分)120例中CVT 34例(28.3%);高概率(6-12分)53例中CVT 49例(92.5%)。
  • 所有低概率CVT患者D-二聚体均>500 μg/L。
  • D-二聚体>675 μg/L(最佳截断值) vs >500 μg/L:敏感度77.7% vs 89.4%,特异度77% vs 66.4%,NPV 90.7% vs 94.6%,准确率77.2% vs 72.4%。

关键数值与推荐

  • 低CVT概率定义为评分0-2分,阴性预测值94.1%。
  • 中概率为3-5分,高概率为6-12分。
  • D-二聚体最佳截断值为>675 μg/L。
  • 联合评分截断≥6分时AUC 0.937。

临床怎么用

  • 对临床疑似CVT患者,可先用6项临床评分分层,低概率且D-二聚体<500 μg/L者CVT可能性极低。
  • 临床评分联合D-二聚体>500 μg/L可提高CVT预测效能,辅助决定是否行神经影像确诊。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate prediction of cerebral venous thrombosis (CVT) by clinical variables and D-dimer levels. METHODS: This prospective multicenter study included consecutive patients with clinically possible CVT. On admission, patients underwent clinical examination, blood sampling for D-dimers measuring (ELISA test), and magnetic resonance/CT venography. Predictive value of clinical variables and D-dimers for CVT was calculated. A clinical score to stratify patients into groups with low, moderate, or high CVT risk was established with multivariate logistic regression. RESULTS: CVT was confirmed in 26.2% (94 of 359) of patients by neuroimaging. The optimal estimate of clinical probability was based on 6 variables: seizure(s) at presentation (4 points), known thrombophilia (4 points), oral contraception (2 points), duration of symptoms >6 days (2 points), worst headache ever (1 point), and focal neurologic deficit at presentation (1 point) (area under the curve [AUC] 0.889). We defined 0 to 2 points as low CVT probability (negative predictive value [NPV] 94.1%). Of the 186 (51.8%) patients who had a low probability score, 11 (5.9%) had CVT. The frequency of CVT was 28.3% (34 of 120) in patients with a moderate (3-5 points) and 92.5% (49 of 53) in patients with a high (6-12 points) probability score. All low CVT probability patients with CVT had D-dimers >500 μg/L. Predictive value of D-dimers for CVT for >675 μg/L (best cutoff) vs >500 μg/L was as follows: sensitivity 77.7%, specificity, 77%, NPV 90.7%, and accuracy 77.2% vs sensitivity 89.4%, specificity 66.4%, NPV 94.6%, and accuracy 72.4%, respectively. Adding the clinical score to D-dimers >500 μg/L resulted in the best CVT prediction score explored (at the cutoff ≥6 points: sensitivity 83%/specificity 86.8%/NPV 93.5%/accuracy 84.4%/AUC 0.937). CONCLUSION: The proposed new clinical score in combination with D-dimers may be helpful for predicting CVT as a pretest score; none of the patients with CVT showed low clinical probability for CVT and D-dimers <500 μg/L. CLINICALTRIALSGOV IDENTIFIER: NCT00924859.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Heldner MR, Zuurbier SM, Li B, et al. Prediction of cerebral venous thrombosis with a new clinical score and D-dimer levels. Neurology. 2020. PMID: 32576633. doi:10.1212/WNL.0000000000009998

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。